Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 3/20 | 0.52 |
| ▸ | YAP1 | P46937 | 1/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 5/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22843441 | 0.90 | TEAD1 (0.51) | TEAD1YAP1SLC6A9ARTLR2 | |
| SCHEMBL22843443 | 0.89 | TEAD1 (0.40) | TEAD1YAP1ARTLR2TLR1 | |
| SCHEMBL22843430 | 0.88 | TEAD1 (0.54) | TEAD1YAP1TLR2TLR1KDM4E | |
| SCHEMBL22843401 | 0.88 | TEAD1 (0.39) | TEAD1YAP1ARTLR2TLR1 | |
| SCHEMBL29438894 | 0.86 | TEAD1 (0.47) | TEAD1YAP1SLC6A9SYKKDM4E | |
| SCHEMBL22718289 | 0.86 | TEAD1 (0.47) | TEAD1YAP1SLC6A9SYKKDM4E | |
| SCHEMBL22843425 | 0.86 | TEAD1 (0.49) | TEAD1YAP1TLR2TLR1KDM4E | |
| SCHEMBL22843451 | 0.86 | TEAD1 (0.54) | TEAD1YAP1TLR2TLR1KDM4E | |
| SCHEMBL22718134 | 0.85 | TEAD1 (0.59) | TEAD1YAP1SLC6A9ARTLR2 | |
| SCHEMBL29438926 | 0.85 | TEAD1 (0.59) | TEAD1YAP1SLC6A9ARTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885SLC6A9 3506/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885SLC6A9 3506/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885YAP1 111/4885SLC6A9 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.